Oregon Prescription Drug Monitoring Program Advisory Commission
January 16. 2026, 1:00 PM Meeting Minutes
Meeting Contact: Stephanie Vesik, Stephanie.g.vesik@oha.oregon.gov, 971-200-9463

Advisory Commission Attendees:

Laura Armstrong (Chair), OD, MEd, FAAO – Optometrist, representing the Board of Optometry and
Maureen McAvoy Jemison – Public member with expertise in information technology
Dan Kennedy, RPh – Oregon State Pharmacy Association
Leah Hickson, DDS – Oregon Dental Association
Katie Zinno – Public member and patient advocate
John McIlveen –Oregon Health Authority (OHA), State Opioid Treatment Authority for Oregon
Tracy Klein, PhD, FNP - Oregon Nurses Association

Absent:

Kaley Bourgeois, ND – Naturopathic physician representing the Oregon Association of Naturopathic Physicians
Lina Dorfmeister CRNA NSPM-c – Pain and addiction management clinic,
Vacant – Physician, representing Oregon Medical Association
Vacant – Physician, representing Osteopathic Physicians and Surgeons of Oregon

OHA Staff Attendees:

Drew Simpson – Information Systems Manager
Stephanie Vesik– Program Coordinator
Tamara Ramirez – PDMP Operations and Coordination Specialist
Ariane Erickson – Research Analyst, overseeing quarterly and annual metrics for PDMP.
Elizabeth McCarthy – Overdose Epidemiologist and PDMP Epidemiologist

Introductions

Members and staff introduced themselves. Laura Armstrong chaired the meeting.

Review of Previous Meeting's Minutes

Corrections: Leah Hickson's name was missing; wording corrected from "advisor" to "advisory."
Motion to approve with changes: Leah moved, John seconded. Approved.

Standing Agenda Items

a. Review quarterly metrics

Quarterly Report
Ariane Erickson shared the Q3 2025 quarterly report, explaining that the Oregon PDMP data are a full calendar quarter behind as we are dependent on our software vendor Bamboo Health for quarterly data extracts. Starting in 2025, Oregon began collecting schedule V controlled substance data and veterinary data from retail pharmacy outlets, creating a 10% increase in total prescription dispensations in the OR PDMP.
Data presented started with prescriber enrollment remaining stable at 86%.
Data continues to show gradual increased use year over year and that integrated PDMP accounts for a significant portion of that as more facilities adopt integration.
Ariane presented and discussed the continued increase in the dispensations of stimulants methylphenidate and amphetamine, with a 9.9% increase from 2024 to 2025. Discussion followed and Ariane was about stimulants followed by asking if there was a seasonal aspect of this following school schedules. It was shared that there was some indication of seasonal trends but additional research would be required.
Gabapentin prescriptions remain a top prescribed drug in Oregon and the rates of dispensation steady.

Discussion of quarterly metrics was concluded with a proposal to shift reporting for semiannual meetings and was approved by the Advisory Commission.

Pharmacy Compliance
Stephanie presented pharmacy information regarding the 2025 update to include veterinary prescriptions. It was noted that there are prescriptions being submitted listed under pet names, or owner and pet name combinations. Stephanie discussed plans for future collaboration with Bamboo Health, Board of Pharmacy, DEA, Oregon DOJ to align reporting under the pet owners name as intended by the legislation to collect veterinary data.

File rejection reports, an automated report provided by vendor Bamboo Health, were discussed as a tool for pharmacy compliance. These reports can be consolidated by OR PDMP staff and then used for purposes of finding frequency patterns of errors across pharmacies for developing widespread educational materials or for pharmacy specific education if there is an significant number of records rejected.

It was shared that the majority of pharmacies were in compliance, with two having vendor-related issues were being addressed.

System users with Oregon Medical Board licenses had their grand renewals updated; 604 medical licenses lapsed or retired.

b. Research study updates

With the absence of PDMP researcher Bryan Loy, Stephanie Vesik shared on his behalf that two research requests are currently under review (Slocum Research & Education; McLean Hospital/CoMagine), and four DUAs were issued in the previous quarter.

c. Subcommittee Activities Update

Liz McCarthy shared a review of the PDMP Advisory Commission Subcommittee risky prescribing measures used to generate educational letters to prescribers across Oregon on a quarterly basis. At each meeting the Subcommittee discusses the existing measures and if any changes or additions need to be made. Recent updates as of January, 2026 include
Co-prescribing opioids with sedatives – to include gabapentin/pregabalin; Opioid-naïve long duration threshold reduced to 31 pills; High MME threshold under review currently with a threshold of 200 MME and considering reducing it to 150 MME. The subcommittee for 2026 decided to create a new measure focusing on stimulants.

An advisory commission member prompted discussion of patient impact stating that the current general guidelines of 90 MME as a threshold and how practitioners are treating guidelines like mandates. It was noted by Liz that the current 200 MME threshold for an educational letter was chosen to provide educational materials only to those identified as possibly having risky prescribing practices and that the PDMP does not have control over prescriber practices or the CDC guidelines prescribers may be understanding as mandate.

d. Legislative Update

SB 841 implemented: PDMP data sharing with Oregon tribes and tribal epidemiology center under new agreements.

Short 2026 session expected; no major PDMP legislative changes anticipate.

Budge Update

Budget stable for next biennium with $35 annual fee and CMS support.

Harold Rogers grant uncertain due to federal shutdown.

Future consideration of fee increase to $50 possible but not active.

Old Business

New Business

Term expirations in July for several members; confirmations received from Dan, Katie, John to continue.

Ongoing outreach to OMA for clinician seat.

Open Issues

Public Comment

Dr. Darryl George raised concerns about PDMP data accuracy, pharmacy reporting errors, and impact on patient care.
Suggested better tracking of provider PDMP checks and error remediation.
Commission acknowledged importance; will consider adding error review to future agendas.

Next Meeting Date:
October 16, 2026